NCT06684184View on ClinicalTrials.gov

Blinatumomab in Refractory Myasthenia Gravis (BLINA-MG)

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Myasthaenia Gravis
Interventions
DRUG

Blinatumomab

The initial dose is 9 µ g, administered intravenously continuously for 5 days, with a total dose of 38.5 µ g. After stopping the medication for one week, the patient received a second infusion of Blinatumomab for a total of 5 days, with a total dose of 38.5 µ g.

All Listed Sponsors
lead

Zhongming Qiu

OTHER

NCT06684184 - Blinatumomab in Refractory Myasthenia Gravis (BLINA-MG) | Biotech Hunter | Biotech Hunter